Teva Pharmaceutical Industries Ltd ADR Stock
The price for the Teva Pharmaceutical Industries Ltd ADR stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.760%).
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
On the other hand, the target price of 13 € is below the current price of 13.15 € for Teva Pharmaceutical Industries Ltd ADR, so the potential is actually -1.14%.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 2 users see the criterium "Management" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | -0.760% | 6.048% | 1.938% | 63.965% | 41.094% | 47.919% | -0.379% |
| Bayer AG ADR | -5.710% | 3.937% | -3.650% | -53.521% | -23.256% | -50.376% | -56.863% |
| Roche Holding AG ADR | -1.630% | -2.512% | -6.422% | -23.644% | -15.675% | -19.410% | - |
| GSK plc ADR | 3.590% | 6.283% | 4.103% | 22.289% | 20.833% | 4.103% | -9.007% |
Comments
Teva Pharmaceutical Industries Limited (NYSE: TEVA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $19.00 price target on the stock, up previously from $12.00.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $15.00 to $17.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $14.00 to $15.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat